Evidence map›Paper›PMID 38764726›Full record

ArticleMedComm2024

m

Qiao-Ru Guo, Guo-Bin Zhang, Wen-Min Zhou, Yu Lu, Xin-Zhu Chen, Zhuo-Fen Deng, Jin-Shuo Li, Hong Bi, Ming-Sheng Wu, Ming-Ran Xie and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in MedComm, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. mMedComm · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qiao-Ru GuoGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and The Fifth Affiliated Hospital Guangzhou Medical University Guangzhou P.R. China.
Guo-Bin ZhangGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and The Fifth Affiliated Hospital Guangzhou Medical University Guangzhou P.R. China.
Wen-Min ZhouGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and The Fifth Affiliated Hospital Guangzhou Medical University Guangzhou P.R. China.
Yu LuGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and The Fifth Affiliated Hospital Guangzhou Medical University Guangzhou P.R. China.
Xin-Zhu ChenGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and The Fifth Affiliated Hospital Guangzhou Medical University Guangzhou P.R. China.
Zhuo-Fen DengGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and The Fifth Affiliated Hospital Guangzhou Medical University Guangzhou P.R. China.
Jin-Shuo LiSchool of Medicine Shanxi Datong University Datong P.R. China.
Hong BiDepartment of Pathology Shanxi Provincial People's Hospital Taiyuan P.R. China.
Ming-Sheng WuDepartment of Thoracic Surgery The First Affiliated Hospital of USTC Division of Life Sciences and Medicine University of Science and Technology of China Hefei P.R. China.
Ming-Ran XieDepartment of Thoracic Surgery The First Affiliated Hospital of USTC Division of Life Sciences and Medicine University of Science and Technology of China Hefei P.R. China.
Yan-Yan YanSchool of Medicine Shanxi Datong University Datong P.R. China.
Jian-Ye ZhangGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and The Fifth Affiliated Hospital Guangzhou Medical University Guangzhou P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a disease with molecular heterogeneity that is closely related to gene mutations and epigenetic changes. The principal histological subtype of lung cancer is non-small cell lung cancer (NSCLC). Long noncoding RNA (lncRNA) is a kind of RNA that is without protein coding function, playing a critical role in the progression of cancer. In this research, the regulatory mechanisms of lncRNA phosphorylase kinase regulatory subunit alpha 1 antisense RNA 1 (PHKA1-AS1) in the progression of NSCLC were explored. The increased level of N6-methyladenosine (m

Indexed as

actinin alpha 4 (ACTN4)long noncoding RNA (lncRNA)metastasisN6‐methyladenosine (m6A) modificationnon‐small cell lung cancer (NSCLC)phosphorylase kinase regulatory subunit alpha 1 antisense RNA 1 (PHKA1‐AS1)ubiquitination

Identifiers

PMID38764726
PMCPMC11099756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.